Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve

NCT00083408 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT00083408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1998
Completion date
May 31, 2005
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma